Cargando…

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent vaccine in preventing hospitalization for COVID-19 (primary outcome) and medically a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Hung Fu, Ackerson, Bradley K., Sy, Lina S., Tubert, Julia E., Luo, Yi, Qiu, Sijia, Lee, Gina S., Bruxvoort, Katia J., Ku, Jennifer H., Florea, Ana, Takhar, Harpreet S., Bathala, Radha, Zhou, Cindy Ke, Esposito, Daina B., Marks, Morgan A., Anderson, Evan J., Talarico, Carla A., Qian, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511551/ https://www.ncbi.nlm.nih.gov/pubmed/37730701 http://dx.doi.org/10.1038/s41467-023-41537-7

Ejemplares similares

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
por: Bruxvoort, Katia J., et al.
Publicado: (2021)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
por: Florea, Ana, et al.
Publicado: (2022)

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

784. Real-world effectiveness of the mRNA-12733-dose primary series against COVID-19 in an immunocompromised population Interim results from a prospective observational cohort study
por: Ku, Jennifer H, et al.
Publicado: (2022)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

EPH124 Prediction Model to Evaluate the Impact of a Next Generation Bivalent Omicron-Containing COVID-19 Booster (MRNA.1273.214) on Hospitalizations in Adults in Germany
por: Müller, A, et al.
Publicado: (2022)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population
por: Anteyi, Kate, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

(8) 5th Dose Bivalent Omicron-Containing Booster Vaccine Against Covid-19 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions
por: Emile-Backer, Magalie, et al.
Publicado: (2023)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

EPH117 Factors Associated with Receipt of Second Dose of mRNA-1273 Vaccine at Walgreens Pharmacies during the COVID-19 Pandemic
por: Roberts, E, et al.
Publicado: (2022)

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages
por: He, Qiaren, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023)

The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report
por: Chen, Ssu-Yu, et al.
Publicado: (2023)

mrna-1273: Breakthrough COVID-19 infection: 3 case reports
Publicado: (2021)

Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years
por: Yogurtcu, Osman N., et al.
Publicado: (2023)

Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?
por: Babicki, Mateusz
Publicado: (2022)

COVID-19 vaccine concerns of health care providers and ancillary staff
por: Lewin, Bruno J., et al.
Publicado: (2022)

A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants
por: Goyal, Lokesh, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rv240ucmib9sdmiepc5dg20f3a